Similarly, both anti-VEGF therapy and immunotherapy are ineffective in highly pro-fibroproliferative tumors, such as pancreatic ductal adenocarcinoma (10), breast cancer, and cholangiocarcinoma, indicating the tumor specificity of the combination therapy (11). The gene discussed is VEGFA; the disease is neoplasm.